Literature DB >> 2523943

The role of three domains in the biological activity of human interferon-alpha.

E N Fish1, K Banerjee, N Stebbing.   

Abstract

Earlier studies showed that minor differences in primary structure among the interferon-alpha (IFN-alpha) protein family are reflected in their potency in selected biological assays. These studies have been extended and results from assays of antiviral, growth inhibitory and 2',5'-oligoadenylate (2-5A) synthetase activities indicate that the various novel hybrid and analog species are differentially biologically active. Overall these observations suggest a correlation between predicted secondary structure characteristics, receptor binding affinity, and 2-5A synthetase, antiviral and growth inhibitory activities. Studies with a consensus IFN-alpha analog particularly implicated the region around residues 78 and 79 as influencing antiviral activity. Neutralization experiments with a monoclonal antibody directed against a conserved region from residues 113 to 149 indicated that although this region of the IFN-alpha molecule may be important for antiviral activity, altering residues at sites removed from this region may reduce the effectiveness of the neutralizing antibody. Receptor binding experiments suggested that no single site at either the amino or carboxyl terminus of IFN-alpha alone determines receptor affinity or biological activity: apparently three distinct domains along IFN-alpha are involved (10-35, 78-107, 123-166). Overall, the data indicate that the three sites contribute toward the active configuration of human IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523943     DOI: 10.1089/jir.1989.9.97

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  10 in total

1.  Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin.

Authors:  Christopher M Moore; Magdalena George; David H Van Thiel
Journal:  Dig Dis Sci       Date:  2011-08-31       Impact factor: 3.199

2.  Characterization of bovine interferon α1: expression in yeast Pichia pastoris, biological activities, and physicochemical characteristics.

Authors:  Jianwei Shao; Chong Cao; Jun Bao; Hongtao Liu; Tongquan Peng; Mingchun Gao; Junwei Wang
Journal:  J Interferon Cytokine Res       Date:  2014-10-24       Impact factor: 2.607

3.  Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.

Authors:  Maria H Sjogren; Robert Sjogren; Michael F Lyons; Michael Ryan; John Santoro; Coleman Smith; K Rajender Reddy; Herbert Bonkovsky; Brooke Huntley; Sima Faris-Young
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

Review 4.  HIV-1 gp41 and type I interferon: sequence homology and biological as well as clinical implications.

Authors:  Y H Chen; Y Xiao; M P Dierich
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

5.  The cloning of cattle interferon-A subtypes isolated from the gut epithelium of rotavirus-infected calves.

Authors:  P J Chaplin; K R Parsons; R A Collins
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

6.  The role of consensus interferon in the current treatment of chronic hepatitis C viral infection.

Authors:  Eleanor N Fish; Stephen A Harrison; Tarek Hassanein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-09

7.  Homology model of human interferon-alpha 8 and its receptor complex.

Authors:  M H Seto; R N Harkins; M Adler; M Whitlow; W B Church; E Croze
Journal:  Protein Sci       Date:  1995-04       Impact factor: 6.725

8.  Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin.

Authors:  Carroll B Leevy
Journal:  Dig Dis Sci       Date:  2008-01-25       Impact factor: 3.199

Review 9.  The yin and yang of viruses and interferons.

Authors:  Ben X Wang; Eleanor N Fish
Journal:  Trends Immunol       Date:  2012-02-07       Impact factor: 16.687

10.  Three-dimensional crystal structure of recombinant murine interferon-beta.

Authors:  T Senda; T Shimazu; S Matsuda; G Kawano; H Shimizu; K T Nakamura; Y Mitsui
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.